Literature DB >> 24549974

Recurrent thrombosis prevention with intravenous immunoglobulin and hydroxychloroquine during pregnancy in a patient with history of catastrophic antiphospholipid syndrome and pregnancy loss.

Nataliya Mar1, Rebecca Kosowicz, Karen Hook.   

Abstract

We report a case of a 36-year old patient with prior history of thrombosis in a setting of antiphospholipid antibody syndrome (APS) as well as pregnancy-associated catastrophic antiphospholipid syndrome (CAPS), resulting in multi-organ infarction and pregnancy loss. The episode of CAPS occurred while she was receiving antepartum low-dose aspirin and therapeutic-dose enoxaparin. This patient presented again at 6 weeks gestation and ultrasounds were consistent with fetal growth restriction, concerning for placental insufficiency and thrombosis. This time, hydroxychloroquine and monthly intravenous immunoglobulin (IVIG) infusions were added to her prophylaxis regimen, resulting in a successful delivery. Platelet count and antiphospholipid antibody titers were routinely monitored throughout pregnancy as markers of disease activity for APS. Current thromboprophylaxis guidelines do not address therapeutic options to prevent further pregnancy morbidity in women who develop recurrent episodes of thrombosis or CAPS despite receiving adequate anti-thrombotic treatment. Use of hydroxychloroquine and IVIG has been associated with good outcomes in this subset of patients.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24549974     DOI: 10.1007/s11239-014-1061-x

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  31 in total

Review 1.  The antiphospholipid syndrome.

Authors:  Jerrold S Levine; D Ware Branch; Joyce Rauch
Journal:  N Engl J Med       Date:  2002-03-07       Impact factor: 91.245

2.  Intravenous immunoglobulin to prevent recurrent thrombosis in the antiphospholipid syndrome.

Authors:  G R Hsiao; R E Wolf; D L Kimpel
Journal:  J Clin Rheumatol       Date:  2001-10       Impact factor: 3.517

Review 3.  Catastrophic antiphospholipid syndrome during pregnancy and puerperium: maternal and fetal characteristics of 15 cases.

Authors:  José A Gómez-Puerta; Ricard Cervera; Gerard Espinosa; Ronald A Asherson; Mario García-Carrasco; Izaias P da Costa; Danieli C O Andrade; Eduardo F Borba; Alexander Makatsaria; Silvia Bucciarelli; Manuel Ramos-Casals; Josep Font
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

4.  Identification of an Fc gamma receptor-independent mechanism by which intravenous immunoglobulin ameliorates antiphospholipid antibody-induced thrombogenic phenotype.

Authors:  S S Pierangeli; R Espinola; X Liu; E N Harris; J E Salmon
Journal:  Arthritis Rheum       Date:  2001-04

Review 5.  Immunomodulatory effects of intravenous immunoglobulins as a treatment for autoimmune diseases, cancer, and recurrent pregnancy loss.

Authors:  Tal Sapir; Miri Blank; Yehuda Shoenfeld
Journal:  Ann N Y Acad Sci       Date:  2005-06       Impact factor: 5.691

6.  Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug.

Authors:  Jacob H Rand; Xiao-Xuan Wu; Anthony S Quinn; Anthony W Ashton; Pojen P Chen; James J Hathcock; Harry A M Andree; Douglas J Taatjes
Journal:  Blood       Date:  2009-11-30       Impact factor: 22.113

Review 7.  Risk factors for venous thromboembolism.

Authors:  Frederick A Anderson; Frederick A Spencer
Journal:  Circulation       Date:  2003-06-17       Impact factor: 29.690

Review 8.  The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome.

Authors:  Reyhan Diz-Kucukkaya; Veysel Sabri Hancer; Bahar Artim-Esen; Yuksel Pekcelen; Murat Inanc
Journal:  J Thromb Thrombolysis       Date:  2010-04       Impact factor: 2.300

9.  Treatment of antiphospholipid antibody syndrome (APS) in pregnancy: a randomized pilot trial comparing low molecular weight heparin to unfractionated heparin.

Authors:  Mary D Stephenson; Penny J Ballem; Peter Tsang; Sue Purkiss; Stephanie Ensworth; Edwina Houlihan; Mary H H Ensom
Journal:  J Obstet Gynaecol Can       Date:  2004-08

10.  Effect of prednisone, aspirin, low molecular weight heparin and intravenous immunoglobulin on outcome of pregnancy in women with antiphospholipid syndrome.

Authors:  Jing Xiao; Jing Xiong; Fufan Zhu; Liang He
Journal:  Exp Ther Med       Date:  2012-10-10       Impact factor: 2.447

View more
  3 in total

Review 1.  Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review.

Authors:  Amelia Ruffatti; Ariela Hoxha; Maria Favaro; Marta Tonello; Anna Colpo; Umberto Cucchini; Alessandra Banzato; Vittorio Pengo
Journal:  Clin Rev Allergy Immunol       Date:  2017-08       Impact factor: 8.667

2.  The role of hydroxychloroquine in catastrophic antiphospholipid syndrome case: Series of two case reports and review of literature.

Authors:  Zakaria Hindi; Mosa Hussein; Abdallah Gad; Abdallah A Khaled; Talal Zahoor
Journal:  SAGE Open Med Case Rep       Date:  2018-06-26

Review 3.  Immunosuppressive Treatment in Antiphospholipid Syndrome: Is It Worth It?

Authors:  Ilaria Mormile; Francescopaolo Granata; Alessandra Punziano; Amato de Paulis; Francesca Wanda Rossi
Journal:  Biomedicines       Date:  2021-02-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.